TY - JOUR
T1 - TCNU (LS 2667), a new active drug in the treatment of advanced colorectal cancer
AU - Gundersen, S.
AU - Dombernowsky, P.
AU - Cavalli, F.
AU - Bruntsch, U.
AU - Renard, J.
AU - Van Glabbeke, M.
AU - Pinedo, H.
PY - 1989
Y1 - 1989
N2 - Fifty-seven patients with advanced measurable or evaluable colorectal cancer not previously treated with chemotherapy and tumor manifestations from colorectal cancer were treated with tauromustine (TCNU), a new nitrosourea with a therapeutic index against murine tumors better to or equal to that of the established nitrosoureas. The dose was 130 mg/m2 orally q 5 weeks. There were one CR and seven PR, for an overall response rate of 14%. Responding sites included the liver (one CR and two PR), lung (four PR) and lymph nodes (two PR). The median duration of response was 33+ weeks (21+ to 34 weeks). The main dose limiting toxicity was myelosuppression which seemed to be cumulative. Subjectively, the drug was well tolerated although most patients experienced nausea and vomiting for some hours. It is concluded that TCNU is a well tolerated compound with limited, but definite antitumor activity against colorectal cancer and that further studies in this disease could be of interest.
AB - Fifty-seven patients with advanced measurable or evaluable colorectal cancer not previously treated with chemotherapy and tumor manifestations from colorectal cancer were treated with tauromustine (TCNU), a new nitrosourea with a therapeutic index against murine tumors better to or equal to that of the established nitrosoureas. The dose was 130 mg/m2 orally q 5 weeks. There were one CR and seven PR, for an overall response rate of 14%. Responding sites included the liver (one CR and two PR), lung (four PR) and lymph nodes (two PR). The median duration of response was 33+ weeks (21+ to 34 weeks). The main dose limiting toxicity was myelosuppression which seemed to be cumulative. Subjectively, the drug was well tolerated although most patients experienced nausea and vomiting for some hours. It is concluded that TCNU is a well tolerated compound with limited, but definite antitumor activity against colorectal cancer and that further studies in this disease could be of interest.
UR - http://www.scopus.com/inward/record.url?scp=0024395508&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024395508&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(89)90394-5
DO - 10.1016/0277-5379(89)90394-5
M3 - Article
C2 - 2759163
AN - SCOPUS:0024395508
SN - 0277-5379
VL - 25
SP - 1095
EP - 1097
JO - European Journal of Cancer and Clinical Oncology
JF - European Journal of Cancer and Clinical Oncology
IS - 7
ER -